AgomAb Therapeutics NV (AGMB)
NASDAQ: AGMB · Real-Time Price · USD
11.42
-0.82 (-6.70%)
At close: May 7, 2026, 4:00 PM EDT
11.35
-0.07 (-0.61%)
After-hours: May 7, 2026, 5:44 PM EDT
AgomAb Therapeutics NV Employees
AgomAb Therapeutics NV had 58 employees as of December 31, 2024. The number of employees increased by 24 or 70.00% compared to the previous year.
Employees
58
Change
24
Growth
70.00%
Revenue / Employee
n/a
Profits / Employee
-$1,574,319
Market Cap
562.41M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 58 | 24 | 70.00% |
| Dec 31, 2023 | 34 | 33 | 3,300.00% |
| Dec 31, 2019 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ProKidney | 231 |
| CorMedix | 191 |
| Entrada Therapeutics | 152 |
| Prime Medicine | 146 |
| Sutro Biopharma | 137 |
| Alpha Tau Medical | 121 |
| Adlai Nortye | 109 |
| Prothena Corporation | 67 |
AGMB News
- 14 days ago - Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook - GlobeNewsWire
- 6 weeks ago - Agomab receives U.S. patent for AGMB-447 - TheFly
- 6 weeks ago - Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 2 months ago - Agomab initiated with an Outperform at Leerink - TheFly
- 2 months ago - Agomab initiated with an Overweight at Morgan Stanley - TheFly
- 2 months ago - Agomab initiated with an Overweight at JPMorgan - TheFly
- 3 months ago - Agomab Announces Closing of Initial Public Offering - GlobeNewsWire
- 3 months ago - Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut - Reuters